Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case

Link to article at PubMed

Int J Infect Dis. 2021 Jul 13:S1201-9712(21)00586-5. doi: 10.1016/j.ijid.2021.07.029. Online ahead of print.


We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy.

PMID:34271202 | DOI:10.1016/j.ijid.2021.07.029

Leave a Reply

Your email address will not be published.